Nestler Sebastian, Grüne Britta, Schilchegger Lydia, Neisius Andreas
Urological Practice, Urogate, Bad Vilbel, Germany.
Department of Urology, University Medical Center, Mannheim, Germany.
Int Urol Nephrol. 2025 Apr 12. doi: 10.1007/s11255-025-04508-z.
To evaluate therapy adherence rates in female patients with idiopathic overactive bladder (iOAB) undergoing therapy with 100AE botulinum toxin A over a 4-year follow-up period.
All female patients who received their first intravesical injection of 100AE botulinum toxin A for iOAB at a single centre between January 2018 and December 2020 were evaluated over a 48-month follow-up for treatment benefit, reduction of urgency incontinence episodes, bladder capacity, repeat injections, adverse events, adherence to therapy, and reasons for discontinuation.
A total of 106 women met our inclusion criteria and 15 were excluded. Of the remaining 91 women, the mean age before the first injection was 64 years and the median urinary incontinence episodes (UIE) was 3.6. After 48 months, 64 patients (70.3%) continued the therapy. Bladder capacity increased by a median of 105-207 cc and the UIE was reduced by 2.64 episodes daily. Complete continence was achieved in 31 patients (34.1%). After the second cycle, 71 patients (78.0%) were satisfied with therapy, with similar results in subsequent cycles. In addition, most patients who adhered to the therapy received four or five rounds of treatments. Adverse events were mainly urinary tract infections (11.8%) in the first cycle and less in subsequent cycles. No de novo clean intermittent self-catheterisation was detected. The reasons for discontinuation among the 27 patients who discontinued therapy were diverse and mostly unmet expectations.
Female patients with iOAB had good therapy adherence to botulinum toxin A, evidenced by stable improvements in UIE and bladder capacity and high rates of satisfaction in patients' self-assessment.
评估在4年随访期内接受100单位A型肉毒杆菌毒素治疗的特发性膀胱过度活动症（iOAB）女性患者的治疗依从率。
对2018年1月至2020年12月期间在单一中心首次接受膀胱内注射100单位A型肉毒杆菌毒素治疗iOAB的所有女性患者进行了48个月的随访，评估治疗效果、尿急失禁发作次数的减少、膀胱容量、重复注射、不良事件、治疗依从性以及停药原因。
共有106名女性符合纳入标准，15名被排除。其余91名女性中，首次注射前的平均年龄为64岁，尿失禁发作次数（UIE）中位数为3.6次。48个月后，64名患者（70.3%）继续接受治疗。膀胱容量中位数增加了105 - 207立方厘米，每日UIE减少了2.64次。31名患者（34.1%）实现了完全控尿。第二个周期后，71名患者（78.0%）对治疗满意，后续周期结果相似。此外，大多数坚持治疗的患者接受了四或五轮治疗。不良事件主要在第一个周期为尿路感染（11.8%），后续周期较少。未检测到新的清洁间歇性自我导尿情况。在27名停药患者中，停药原因多种多样，主要是期望未得到满足。
iOAB女性患者对A型肉毒杆菌毒素治疗具有良好的依从性，这体现在UIE和膀胱容量的稳定改善以及患者自我评估的高满意度上。
